Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.
暂无分享,去创建一个
R. Krance | K. Leung | H. Heslop | C. Bollard | S. Gottschalk | M. Brenner | H. Weiss | Shakila P. Khan | A. Mahajan | G. Carrum | J. A. Arce | A. Kennedy-Nasser | James A. Arce
[1] P. Tsirigotis,et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine‐based preparative regimen , 2006, British journal of haematology.
[2] N. Geller,et al. Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation , 2006, British journal of haematology.
[3] H. Schrezenmeier,et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia , 2006, Bone Marrow Transplantation.
[4] F. Locatelli,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party , 2005, Bone Marrow Transplantation.
[5] R. Krance,et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) , 2005, Bone Marrow Transplantation.
[6] R. Krance,et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab , 2005, Bone Marrow Transplantation.
[7] J. Passweg,et al. Immunosuppression with ALG and CsA is first line treatment in children with SAA lacking an HLA identical sibling , 2005, Pediatric blood & cancer.
[8] Y. Lee,et al. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia , 2005, Bone Marrow Transplantation.
[9] S. Ball,et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning , 2005, Bone Marrow Transplantation.
[10] G. Hale,et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] R. Krance,et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.
[12] R. Porcher,et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. , 2004, Blood.
[13] Raymond J Carroll,et al. A Reanalysis of Thyroid Neoplasms in the Israeli Tinea Capitis Study Accounting for Dose Uncertainties , 2004, Radiation research.
[14] F. Locatelli,et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. , 2004, Haematologica.
[15] H. Heimpel,et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. , 2003, Blood.
[16] C. Craddock,et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.
[17] G. Vassiliou,et al. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low‐dose total body irradiation, cyclophosphamide and Campath , 2001, British journal of haematology.
[18] G. Hale,et al. The CD52 antigen and development of the CAMPATH antibodies. , 2001, Cytotherapy.
[19] G. Morgan,et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. , 2001, Cytotherapy.
[20] S. Mackinnon,et al. CAMPATH-1 antibodies in stem-cell transplantation. , 2001, Cytotherapy.
[21] R. Collins,et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] H. Deeg,et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] T. Barbui,et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Tra , 2000, Blood.
[24] J. Passweg,et al. Current Results of Bone Marrow Transplantation in Patients with Acquired Severe Aplastic Anemia , 2000, Acta Haematologica.
[25] D. Margolis,et al. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. , 2000, Seminars in hematology.
[26] R. Collins,et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] J. V. Stone,et al. Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .
[28] J. Marsh,et al. Treatment options in severe aplastic anaemia , 1998, The Lancet.
[29] R. Storb,et al. Primary Treatment of Acquired Aplastic Anemia: Outcomes with Bone Marrow Transplantation and Immunosuppressive Therapy , 1997, Annals of Internal Medicine.
[30] H. Deeg,et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. , 1996, Transplantation.
[31] H. Deeg,et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. , 1996, Blood.
[32] N. Young,et al. The treatment of severe acquired aplastic anemia. , 1995, Blood.
[33] H. Deeg,et al. Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. , 1994, Blood.
[34] A. Gratwohl,et al. Late clonal complications in severe aplastic anemia. , 1994, Leukemia & lymphoma.
[35] A. Rimm,et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. , 1992, Blood.
[36] M. Horowitz,et al. IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). , 1989, Bone marrow transplantation.
[37] A. Gratwohl,et al. Late haematological complications in severe aplastic anaemia , 1988, British journal of haematology.
[38] Apperley,et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. , 1986, Blood.
[39] D. Nathan,et al. Selection of patients for bone marrow transplantation in severe aplastic anemia. , 1975, Blood.